Outpatient register of patients who have suffered a myocardial infarction (REGATA): prospective follow-up data and outcomes

Aim      To determine the factors that influence the long-term prognosis in patients after myocardial infarction (MI) as a part of the prospective REGistry of pATients after myocArdial infarction (REGATA).

Material and methods  In 2012–2013, 481 post-myocardial infarction patients were included into the REGATA registry; 247 (51.4 %) were men, median age 72 [62; 78] years. The median duration of prospective follow-up after the inclusion into the registry was 6.1 [4.0–6.6] years. Data were obtained for 474 (98.5 %) patients. Statistical analysis was performed with the Microsoft Excel 2010, StatsoftStatistica10.0 software and partially manually by formulas. Methods of descriptive statistics were used. For quantitative variables with normal distribution, mean values and standard deviations were calculated; intergroup differences were evaluated with Student’s t-test. Differences between groups of survived and deceased patients were evaluated with a nonparametric method using the Pearson’s chi-squared test with a Yates's correction, and the Fisher’s exact test. When the frequency of absent data for the studied variable exceeded 20 %, this variable was not included into the analysis. The 6-year survival was analyzed by the Kaplan-Meier method. Fatal outcomes were analyzed with the Cox proportional hazards regression model. Differences were considered significant at p<0.05.

Results During the follow-up period, there were 200 (41.6 %) cases of all-cause death and 123 (25.6 %) cases of cardiovascular death; 39 (8.1 %) of patients had acute cerebrovascular disease (ACVD) and 36 (7.5 %) had recurrent myocardial infarction. The median time from the inclusion into the registry to death was 3.4 [1.6; 5.1] years. A higher risk of all-cause death was significantly associated with factors of age (one-year relative risk, RR, 1.03; 95 % confidence interval, CI, 1.02–1.05; р<0.001), III-IV functional class angina (RR, 1.76; 95 % CI, 1.22–2.53; p=0.003), history of ACVD (RR, 2.12; 95 % CI, 1.50–2.98; p<0.001), atrial fibrillation (AF) (RR, 1.52; 95 % CI, 1.10–2.12; р=0.01), diabetes mellitus (DM) (RR, 1.53; 95 % CI, 1.11–2.10; p=0.009), chronic obstructive pulmonary disease (COPD) (RR, 1.77; 95 % CI, 1.20–2.62; p=0.004), and reduced hemoglobin (RR, 2.09; 95 % CI, 1.31–3.33; p=0.002). A lower risk of death was associated with administration of antiplatelets (RR, 0.57; 95 % CI, 0.37–0.89; p=0.01), angiotensin-converting enzyme (ACE) inhibitors /angiotensin II receptor blockers (ARB) (RR, 0.51; 95 % CI, 0.33–0.78; p=0.002), and statins (RR, 0.48; 95 % CI, 0.34–0.67; p<0.001). A higher risk of nonfatal stroke during the follow-up was significantly associated with age (one-year RR, 1.05; 95 % CI, 1.01–1.09; р=0.02), history of ACVD (RR, 2.74; 95 % CI, 1.33–5.63; p=0.006), and DM (RR, 2.43; 95 % CI, 1.17–5.06; p=0.02), and a higher risk of nonfatal stroke was significantly associated with a history of ACVD (RR, 1.70; 95 % CI, 1.44–2.01; p<0.001), DM (RR, 2.33; 95 % CI, 1.13–4.84; p=0.02), and COPD (RR, 2.47; 95 % CI, 1.02–6.00; p=0.06).

Conclusion      In the outpatient REGATA registry that included patients with MI at any previous time, the death rate for 6 years of follow-up was 41.6 %. In 61.5 % of cases, death was caused by cardiovascular diseases. In clinical practice in long-term, a higher risk of unfavorable outcome was associated with old age, III-IV functional class angina, a history of ACVD, AF, DM, and COPD while a lower risk was associated with the administration of antiplatelets, ACE inhibitors/ARB, and statins.

1. Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Flaxman A et al. The Global Burden of Ischemic Heart Disease in 1990 and 2010: The Global Burden of Disease 2010 Study. Circulation. 2014;129(14):1493–501. DOI: 10.1161/CIRCULATIONAHA.113.004046

2. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW et al. Heart Disease and Stroke Statistics–2021 Update: A Report From the American Heart Association. Circulation. 2021;143(8):e254–743. DOI: 10.1161/CIR.0000000000000950

3. Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. European Heart Journal. 2016;37(42):3232–45. DOI: 10.1093/eurheartj/ehw334

4. Yakushin S.S., Filippov E.V. Analysis of mortality rate from diseases of circulatory system and cardiovascular diseases in the Ryazan region in the period 2012-2016. Eruditio Juvenium. 2018;6(3):448–61. DOI: 10.23888/HMJ201863448-461

5. Parshikova E.N., Filippov E.V. Mortality from all causes in patients with myocardial infarction with elevation of st segment depending on the type of reperfusion therapy (data of Ryazan region, 2018-2020). I.P. Pavlov Russian Medical Biological Herald. 2020;28(4):479–87. DOI: 10.23888/PAVLOVJ2020284479-487

6. Wallentin L, Kristensen SD, Anderson JL, Tubaro M, Sendon JLL, Granger CB et al. How can we optimize the processes of care for acute coronary syndromes to improve outcomes? American Heart Journal. 2014;168(5):622-631.e2. DOI: 10.1016/j.ahj.2014.07.006

7. Smolina K, Wright FL, Rayner M, Goldacre MJ. Long-Term Survival and Recurrence After Acute Myocardial Infarction in England, 2004 to 2010. Circulation: Cardiovascular Quality and Outcomes. 2012;5(4):532–40. DOI: 10.1161/CIRCOUTCOMES.111.964700

8. Campo G, Saia F, Guastaroba P, Marchesini J, Varani E, Manari A et al. Prognostic Impact of Hospital Readmissions After Primary Percutaneous Coronary Intervention. Archives of Internal Medicine. 2011;171(21):1948–9. DOI: 10.1001/archinternmed.2011.536

9. Johansson S, Rosengren A, Young K, Jennings E. Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review. BMC Cardiovascular Disorders. 2017;17(1):53. DOI: 10.1186/s12872-017-0482-9

10. Boytsov S.A., Pogosova N.V., Bubnova M.G., Drapkina O.M., Gavrilova N.E., Yeganyan R.A. et al. Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018;23(6):7–122. DOI: 10.15829/1560-4071-2018-6-7-122

11. Garganeeva A.A., Kuzheleva E.A., Tukish O.V. The role of treatment adherence after myocardial infarction (according to the acute myocardial infarction registry). Complex Issues of Cardiovascular Diseases. 2019;8(4):56–64. DOI: 10.17802/2306-1278-2019-8-4-56-64

12. Malay L.N., Davidovich I.M. Khabarovsk register of acute myocardial infarction: the analysis of long-term prognosis and long-term medical treatment compliance. Far Eastern Medical Journal. 2017;2:43–8.

13. Pereverzeva K.G., Yakushin S.S., Gracheva A.I., Lukyanov M.M., Drapkina O.M. Post-myocardial infarction patients: a comparison of management by a physician and a cardiologist according to the REGATA register. Cardiovascular Therapy and Prevention. 2020;19(3):13–9. DOI: 10.15829/1728-8800-2020-2525

14. Helsinki Declaration of the World Medical Association. Ethical principles in conducting medical research with the involvement of a person. Medical ethics. 2014;2(1):3–6.

15. Gliklich R. Good Practice for Patient Registries. AHRQ Annual Meeting. 2008. Av. at: https://www.powershow.com/view2b/478c80-NWQ2Z/Good_Practice_for_Patient_Registries_AHRQ_Annual_Meeting_Bethesda_MD_September_9_2008_Speaker_Richard_Gliklich_MD_Principal_Investigator_Outcome_DEcIDE_Center_President_Outcome_Cambridge_MA_powerpoint_ppt_presentation.

16. Martsevich S.Yu., Gynzburg M.L., Kutishenko N.P., Deev A.D., Smirnov V.P., Drozdova L.Yu. et al. The LIS study (Lyubertsy study on mortality rate in patients after acute myocardial infarction). evaluation of drug therapy. Рart 2. Influence of previous drug treatment on long-term life prognosis. Rational Pharmacotherapy in Cardiology. 2012;8(6):738–45. DOI: 10.20996/1819-6446-2012-8-6-738-745

17. Martsevich S.Yu., Ginzburg M.L., Kutishenko N.P., Deev A.D., Smirnov V.P., Drozdova L.Yu. et al. Lyubertsy mortality study (LMS): factors influencing the long-term survival after myocardial infarction. The Russian Journal of Preventive Medicine. 2013;16(2–1):32–8.

18. Nauta ST, Deckers JW, Akkerhuis KM, van Domburg RT. Short- and Long-Term Mortality After Myocardial Infarction in Patients With and Without Diabetes: Changes from 1985 to 2008. Diabetes Care. 2012;35(10):2043–7. DOI: 10.2337/dc11-2462

19. Rapsomaniki E, Shah A, Perel P, Denaxas S, George J, Nicholas O et al. Prognostic models for stable coronary artery disease based on electronic health record cohort of 102 023 patients. European Heart Journal. 2014;35(13):844–52. DOI: 10.1093/eurheartj/eht533

20. Deckers JW, van Domburg RT, Akkerhuis M, Nauta ST. Relation of Admission Glucose Levels, Short- and Long-Term (20-Year) Mortality After Acute Myocardial Infarction. The American Journal of Cardiology. 2013;112(9):1306–10. DOI: 10.1016/j.amjcard.2013.06.007

21. Nauta ST, van Domburg RT, Nuis R-J, Akkerhuis M, Deckers JW. Decline in 20-year mortality after myocardial infarction in patients with chronic kidney disease: evolution from the prethrombolysis to the percutaneous coronary intervention era. Kidney International. 2013;84(2):353–8. DOI: 10.1038/ki.2013.71

22. Rapsomaniki E, Thuresson M, Yang E, Blin P, Hunt P, Chung S-C et al. Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction. European Heart Journal - Quality of Care and Clinical Outcomes. 2016;2(3):172–83. DOI: 10.1093/ehjqcco/qcw004